China’s Healthcare AI Strategy: From National Goals to Investment Opportunities
China is rapidly advancing its integration of artificial intelligence into healthcare, driven by national policy and growing investor confidence. In late 2025, the National Health Commission and four other authorities issued a directive calling for broader AI application across the country’s health sector. The vision is clear: AI-assisted diagnosis and treatment will become standard in primary-level institutions for 900 million citizens by 2030.
This strategic push aligns with broader national ambitions, including a focus on embodied AI as a major priority in China’s latest five-year plan. To support this, the government has launched a new $138 billion national venture capital guidance fund, with AI identified as a key target for investment.
Investment interest in China’s AI healthcare sector is intensifying. A top-performing fund managed by China Asset Management Co. Has outperformed 98% of its peers by betting on the AI value chain, including healthcare applications. The fund manager emphasizes that Chinese AI stocks are not in bubble territory and sees strong opportunities across the value chain—from chipmakers and internet giants to healthcare innovators.
Analysts highlight China’s cost advantages in drug development and a growing number of licensing deals as key drivers of optimism in the healthcare AI space. Despite caution on broader consumer stocks, experts remain bullish on China’s potential to lead in AI innovation and global competitiveness, particularly in sectors where technology can address large-scale public health needs.
As AI moves from experimental pilots to nationwide implementation in clinics and hospitals, China’s approach combines top-down policy direction with market-driven innovation. The coming years will test whether this strategy can deliver measurable improvements in access, accuracy, and efficiency in healthcare for hundreds of millions of people.